Andrew A. Lane

This paper develops LIME, a bacterial platform that engagers T and NK cells to target tumors, showing enhanced cytotoxicity and immune response in preclinical models.

This study identifies a unique metabolic plasticity mechanism in AML cells through protein S-acylation, which is inhibited by TOFA and a glutaminase inhibitor combination.

The paper identifies recipient stem-cell persistence and T-cell dysregulation as predictors of relapse after HSCT in AML/MDS by analyzing single-cell RNA and TCR sequencing data.

This paper uses Dynamic BH3 Profiling to predict clinical outcomes in AML by assessing drug-induced apoptotic priming in patient samples.

The paper identifies EIF4A1 as a vulnerability in AML cells and shows that combining Zotatifin with Venetoclax enhances apoptosis and survival in AML models.

This study identifies a targetable dependency on noncanonical PI3Kγ signaling in acute leukemias, showing that PI3Kγ inhibition with eganelisib improves survival when combined with cytarabine.

This study uses whole genome sequencing to analyze PDGFR-rearranged hypereosinophilic syndrome, finding simple genomics with the PDGFR rearrangement as the only recurrent driver event.

The paper develops a method to detect mitochondrial mutations from single-cell RNA-seq to identify clonal expansions in human hematopoiesis.